Ibogaine + Texas IMPACT
Follow the state-backed Texas ibogaine research effort without flattening announced, selected, contracted, enrolling, and running into the same status.
Context behind the headlines.
A living reference layer for the recurring compounds, companies, concepts, and regulators shaping the psychedelic story.
19 live dossiers
5 entity types
6 core starting points
Start with the dossiers most likely to recur in reporting, browse the full wiki by entity type, or check what changed most recently.
Primary research surface
Start with the source trail, then read the story.
The Wiki is the reference layer behind SCM reporting: compounds, programs, companies, people, regulators, policy lanes, and source dossiers kept close to the evidence that supports them.
5-MeO-DMT, mebufotenin, GH001, BPL-003
Keep the compound-name layer separate from company-specific programs, formulations, routes, evidence tiers, and sponsor claims.
GH Research
Use the company page as a stable reference for GH001 context, then read the reporting for the evidence and naming caveats.
Class-grouped atlas
Browse by substance family, institution, and evidence lane.
The alphabetical browse stays below. This layer gives readers the chemistry-and-context map Alex asked for: tryptamines separate from phenethylamines, lysergamides, dissociatives, plant/fungal medicines, atypicals, companies, and regulator/trial infrastructure.
Tryptamines
Indole / tryptamine-family compounds and program pages. This keeps 5-MeO-DMT, mebufotenin, and psilocybin together without collapsing compound, formulation, and sponsor claims.
Next gaps: Psilocin · DPT / DiPT / MET family pages
Phenethylamines / entactogens
MDMA and adjacent phenethylamine / empathogen lanes, separated from classic tryptamine stories and kept close to the Lykos / MAPS regulatory record.
Next gaps: MDA / methylone · 2C-B / 2C family
Lysergamides / ergolines
LSD, LSA/ergine, and related lysergamide history belong in their own lane so they do not disappear inside generic “classic psychedelic” language.
Next gaps: LSD · LSA / ergine · Morning glory / Hawaiian baby woodrose
Dissociatives / arylcyclohexylamines
Ketamine and related dissociative pages need a separate evidence and safety vocabulary from serotonergic psychedelics.
Next gaps: Esketamine · PCP / MXE history
Plant medicines / fungi
Botanical, fungal, and tradition-linked pages where organism, compound, ceremony, and Western reception need to stay distinct.
Next gaps: Peyote / Lophophora · San Pedro / huachuma · Ayahuasca · Amanita muscaria
Atypicals / cannabinoids / other
A visible holding lane for substances that do not fit cleanly into tryptamine, phenethylamine, lysergamide, or dissociative buckets.
Next gaps: Salvia divinorum · Cannabis / cannabinoids · Kava and other adjacent altered-state materials
Companies / organizations
Sponsors, nonprofits, and company-name trails that keep program claims attached to the right entity.
Next gaps: atai · Otsuka / Transcend · Psyence
Regulators / policy / trials
The institutional lane: regulators, indications, state programs, trial infrastructure, and status ladders.
Next gaps: DEA · ClinicalTrials.gov · Oregon Psilocybin Services · Colorado Natural Medicine
Browse by research job
Find the right surface before you follow the claim.
These groupings are intentionally practical: compounds, programs, companies, people, policy infrastructure, and source trails. They point readers toward the page type that best matches the question they actually have.
Compounds
Core substance pages and naming layers that recur across SCM reporting.
Programs / formulations
Where the compound layer becomes a company asset, route, trial record, or approval path.
Companies / institutions
Company and institution pages that help track sponsor language, governance, and program continuity.
People / organizations
Historical and cultural nodes where source provenance and context matter as much as biography.
Policy / trial infrastructure
Regulator, indication, and policy pages that shape how claims move from idea to public record.
Source trails
Reader paths where the key move is separating source status from interpretation.
News ↔ Wiki ↔ Changelog
Use the Wiki as the stable layer, not the whole story.
Texas ibogaine loop
Start with the Wiki dossier, read the reporting, then check the site changelog when the source trail changes.
5-MeO program loop
Move between compound, company, and article layers without collapsing the assets into one generic label.
Core dossiers
Start with the names and institutions that keep showing up.
These are the dossiers most likely to recur across coverage, regulation, and company tracking.
Ibogaine
Schedule I in US; legal in Mexico; active research for OUD and TBI; DoD interest
Mebufotenin
Clinically notable phase 2b signal sits under a messy naming stack: alias/synonym layer includes 5-MeO-DMT, while GH001 is the inhaled program/formulation under study in TRD
GH Research
GH001 / inhaled mebufotenin program moving toward Phase 3 planning after Jan. 2026 clinical-hold lift; phase 2b TRD results published Mar. 25, 2026
MDMA
Schedule I in US; FDA rejected Lykos NDA August 2024; Transcend/Otsuka methylone analog in Phase 3
Psilocybin
Schedule I in US; approved in Australia for TRD and PTSD; extensive Phase 2/3 trials globally
FDA
Active regulator for multiple psychedelic INDs; midomafetamine NDA reviewed in June 2024 and later rejected via Complete Response Letter
Browse by type
Move through the wiki by entity type.
Jump into the full grouped lists below, with a few representative entries surfaced in each category.
Full browse
Browse the whole reference surface.
Every dossier remains directly reachable below, grouped by entity type and still sourced from the live wiki collection.
Companies
Compass Pathways
Phase 3 COMP360 for TRD underway; FDA accepted IND application for PTSD in January 2026
Cybin, now Helus Pharma
Phase 3 PARADIGM program underway for HLP003/CYB003; Eric So resumed as interim CEO on Apr. 20, 2026 after Michael Cola’s short tenure ended at board request
GH Research
GH001 / inhaled mebufotenin program moving toward Phase 3 planning after Jan. 2026 clinical-hold lift; phase 2b TRD results published Mar. 25, 2026
Lykos Therapeutics
Seeking Phase 3 redesign following FDA Complete Response Letter (August 2024)
MAPS (Multidisciplinary Association for Psychedelic Studies)
Active nonprofit research and policy organization; MDMA-assisted therapy remains investigational and MAPS continues public education and program context
Resilient Pharmaceuticals
Formerly Lykos Therapeutics; CIPO name-change record lists July 28, 2025; public reporting followed in late August 2025; MDMA/PTSD program remains post-CRL
Compounds
Ibogaine
Schedule I in US; legal in Mexico; active research for OUD and TBI; DoD interest
MDMA
Schedule I in US; FDA rejected Lykos NDA August 2024; Transcend/Otsuka methylone analog in Phase 3
Mebufotenin
Clinically notable phase 2b signal sits under a messy naming stack: alias/synonym layer includes 5-MeO-DMT, while GH001 is the inhaled program/formulation under study in TRD
Psilocybin
Schedule I in US; approved in Australia for TRD and PTSD; extensive Phase 2/3 trials globally
Concepts
MDMA-Assisted Therapy
No approved treatment in US; Phase 3 redesign underway at Lykos
Treatment-Resistant Depression (TRD)
Active research area; psilocybin showing signal but mixed Phase 2/3 results
Regulators
FDA
Active regulator for multiple psychedelic INDs; midomafetamine NDA reviewed in June 2024 and later rejected via Complete Response Letter
People
María Sabina
Deceased; enduring figure in psilocybin history and in debates over colonial extractivism
R. Gordon Wasson
Deceased; enduring and contested figure in psilocybin history
Ram Dass
Deceased; enduring influence through Be Here Now, archival talks, and later spiritual-teaching work
Terence McKenna
Deceased; psychedelic philosopher, writer, speaker, and archival subject
Timothy Leary
Deceased; enduring counterculture symbol and reference point in psychedelic history
Valentina Pavlovna Wasson
Deceased; pediatrician, co-author, and under-described figure in mushroom history